In Vitro Diagnostics | Research, Development, Test, and Evaluation
Emerging Infectious Disease
MRIGlobal’s emerging infectious disease services span all stages of the in vitro diagnostic product development process, beginning with research and development through product clearance and launch.
Our infectious disease diagnostics R&D and IVD product development capabilities include, but are not limited to:
- Development of methods, platforms, and molecular and immunological assays
- Turnkey, outsourcing solutions for commercial and government clients
- Accelerated product development through analytical verification and clinical validation phases
Capabilities
MRIGlobal offers comprehensive assay and protocol development for the diagnosis of emerging infectious disease for Molecular and Immunological, Next Generation Sequencing, Advanced Bioinformatics, and Prototype Development:
- Limit of Detection
- Inclusivity (Reactivity)
- Exclusivity (Cross-Reactivity)
- Interference
- Reproducibility
- Sensitivity and Specificity
- Methods Comparison
- Reference Testing (i.e. culture, COVID CDC))
- Discrepancy Analysis (i.e. sequencing)
- Sample sourcing and testing
- Accelerated and Real Time
- Storage Capacity with 24/7 remote monitoring
Our Staff
Kyle Parker inspects a reagent cartridge prior to loading clinical samples for analysis with a point-of-care device.
MRIGlobal scientists conduct research and development with commercial companies to improve emerging infectious disease diagnostic technologies with the goal of advancing these technologies into verification and validation phases of clinical product development.
Work with us
MRIGlobal looks forward to contributing our expertise where it matters most.
Use our Project Quote Tool to learn more about how we can help with your next endeavor.